Name: India and the Patent Wars: Pharmaceuticals in the New Intellectual Property Regime (The Culture and Politics of Health Care Work) (en Inglés)
Price: 707743.00 COP
Availability: InStock
Author: Murphy Halliburton
ISBN: 9781501713460

portada India and the Patent Wars: Pharmaceuticals in the New Intellectual Property Regime (The Culture and Politics of Health Care Work) (en Inglés)

Formato

Libro Físico

Editorial

ILR Press

Autor

Murphy Halliburton

Idioma

Inglés

N° páginas

202

Encuadernación

Tapa Dura

ISBN13

9781501713460

Categorías

La industria farmacéutica

India and the Patent Wars: Pharmaceuticals in the New Intellectual Property Regime (The Culture and Politics of Health Care Work) (en Inglés)

Murphy Halliburton (Autor) · ILR Press · Tapa Dura

Libro Nuevo

$ 707.743

$ 1.088.835

Ahorras: $ 381.092

35% descuento

Envío normal

Origen: Estados Unidos (Costos de importación incluídos en el precio)

Se enviará desde nuestra bodega entre el Miércoles 19 de Junio y el Miércoles 03 de Julio.

Lo recibirás en cualquier lugar de Colombia entre 1 y 5 días hábiles luego del envío.

Reseña del libro "India and the Patent Wars: Pharmaceuticals in the New Intellectual Property Regime (The Culture and Politics of Health Care Work) (en Inglés)"

India and the Patent Wars contributes to an international debate over the costs of medicine and restrictions on access under stringent patent laws showing how activists and drug companies in low-income countries seize agency and exert influence over these processes. Murphy Halliburton contributes to analyses of globalization within the fields of anthropology, sociology, law, and public health by drawing on interviews and ethnographic work with pharmaceutical producers in India and the United States.India has been at the center of emerging controversies around patent rights related to pharmaceutical production and local medical knowledge. Halliburton shows that Big Pharma is not all-powerful, and that local activists and practitioners of ayurveda, India’s largest indigenous medical system, have been able to undermine the aspirations of multinational companies and the WTO. Halliburton traces how key drug prices have gone down, not up, in low-income countries under the new patent regime through partnerships between US- and India-based companies, but warns us to be aware of access to essential medicines in low- and middle-income countries going forward.